Johnathon Liddicoat

Jan 15, 2025 | nature.com | Johnathon Liddicoat |Gabriela Lenarczyk |Mateo Aboy |Timo Minssen |Sebastian Mann

Can artificial intelligence improve clinical trial design? Despite their importance in medicine, over 40% of trials involve flawed protocols. We introduce and propose the development of application-specific language models (ASLMs) for clinical trial design across three phases: ASLM development by regulatory agencies, customization by Health Technology Assessment bodies, and deployment to stakeholders. This strategy could enhance trial efficiency, inclusivity, and safety, leading to more representative, cost-effective clinical trials.